Article
Drug Cost Implications Highlight SPT Week in Review
Author(s):
Top news of the week from Specialty Pharmacy Times.
Switch to Extended Half-Life Hemophilia Factor Products Found to Double Costs
Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.
Drug Costs Responsible for Nearly Entire Price Tag of Hereditary Angioedema Care
Pharmacy benefit manager reports specialty drugs drive 97% of spending for hereditary angioedema care.
Specialty Drug Spending Grows While Traditional Medicine Spending Drops
Spending on specialty medications is rapidly approaching half of overall medicine spending from a small volume of prescriptions filled.
Specialty Drugs Power Growth in Pharmacy Benefit Spend
New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.
Adherence Lacking to High-Cost Multiple Sclerosis Disease-Modifying Drugs
Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.
FDA Grants Orphan Drug Designation to MDL-101 for Congenital Muscular Dystrophy Type 1a
